- Home
- GYRE vs LQDT Comparison
GYRE vs LQDT Comparison
Compare GYRE & LQDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- LQDT
- Stock Information
- Founded
- GYRE 2002
- LQDT 1999
- Country
- GYRE United States
- LQDT United States
- Employees
- GYRE N/A
- LQDT N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- LQDT Catalog/Specialty Distribution
- Sector
- GYRE Health Care
- LQDT Consumer Discretionary
- Exchange
- GYRE Nasdaq
- LQDT Nasdaq
- Market Cap
- GYRE 897.1M
- LQDT 859.6M
- IPO Year
- GYRE N/A
- LQDT 2006
- Fundamental
- Price
- GYRE $7.28
- LQDT $25.34
- Analyst Decision
- GYRE Strong Buy
- LQDT Strong Buy
- Analyst Count
- GYRE 1
- LQDT 2
- Target Price
- GYRE $18.00
- LQDT $38.50
- AVG Volume (30 Days)
- GYRE 92.0K
- LQDT 187.7K
- Earning Date
- GYRE 11-12-2025
- LQDT 08-07-2025
- Dividend Yield
- GYRE N/A
- LQDT N/A
- EPS Growth
- GYRE N/A
- LQDT 33.77
- EPS
- GYRE 0.02
- LQDT 0.83
- Revenue
- GYRE $102,189,000.00
- LQDT $465,508,000.00
- Revenue This Year
- GYRE $16.80
- LQDT $31.57
- Revenue Next Year
- GYRE $50.29
- LQDT $2.58
- P/E Ratio
- GYRE $428.23
- LQDT $30.30
- Revenue Growth
- GYRE N/A
- LQDT 38.40
- 52 Week Low
- GYRE $6.11
- LQDT $21.23
- 52 Week High
- GYRE $19.00
- LQDT $39.72
- Technical
- Relative Strength Index (RSI)
- GYRE 44.66
- LQDT 35.84
- Support Level
- GYRE $7.20
- LQDT $26.92
- Resistance Level
- GYRE $7.72
- LQDT $27.88
- Average True Range (ATR)
- GYRE 0.28
- LQDT 0.69
- MACD
- GYRE -0.01
- LQDT -0.27
- Stochastic Oscillator
- GYRE 28.58
- LQDT 4.40
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About LQDT Liquidity Services Inc.
Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Capital Assets Group (CAG), Retail Supply Chain Group (RSCG), and Machinio. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.